<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Acurx Pharmaceuticals Llc — News on 6ix</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc</link>
<description>Latest news and press releases for Acurx Pharmaceuticals Llc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/acurx-pharmaceuticals-llc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835426e78dffbe2df0e1469.webp</url>
<title>Acurx Pharmaceuticals Llc</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc</link>
</image>
<item>
<title>Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-12-2026-conference-call-and-provide-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-12-2026-conference-call-and-provide-business-update</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 am ET before the U.S. financial markets open.</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-announces-closing-of-up-to-dollar71-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-announces-closing-of-up-to-dollar71-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Thu, 16 Apr 2026 20:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the closing of its previously announced registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.03 per share (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In addition, in a</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-announces-up-to-dollar71-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-announces-up-to-dollar71-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>$2.5 million upfront with up to an additional $4.6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrantsSTATEN</description>
</item>
<item>
<title>New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/new-to-the-street-resigns-acurx-pharmaceuticals-inc-nasdaqacxp-to-continue-long-form-interview-series-outdoor-media-campaigns-and-accredited-investor-events</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/new-to-the-street-resigns-acurx-pharmaceuticals-inc-nasdaqacxp-to-continue-long-form-interview-series-outdoor-media-campaigns-and-accredited-investor-events</guid>
<pubDate>Tue, 07 Apr 2026 13:00:00 GMT</pubDate>
<description>Three Consecutive Years of Ongoing Predictable Media™ Partnership NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / New to The Street, one of the longest-running sponsored business television brands, proudly announces the re-signing of Acurx ...</description>
</item>
<item>
<title>Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/korean-patent-office-grants-acurx-pharmaceuticals-new-patent-for-dna-polymerase-iiic-inhibitors</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/korean-patent-office-grants-acurx-pharmaceuticals-new-patent-for-dna-polymerase-iiic-inhibitors</guid>
<pubDate>Mon, 30 Mar 2026 11:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Korean Intellectual Property Office (KIPO) has granted a new patent which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, which further strengthen Acurx's intellectual property portfolio and rep</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-reports-full-year-and-fourth-quarter-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-reports-full-year-and-fourth-quarter-results-and-provides-business-update</guid>
<pubDate>Fri, 13 Mar 2026 11:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025.</description>
</item>
<item>
<title>Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-new-ibezapolstat-clinical-trial-program-in-patients-with-recurrent-cdi-that-has-the-potential-to-shift-the-paradigm-of-treatment-and-prevention-of-c-difficile-infection</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-new-ibezapolstat-clinical-trial-program-in-patients-with-recurrent-cdi-that-has-the-potential-to-shift-the-paradigm-of-treatment-and-prevention-of-c-difficile-infection</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical TrialsAcurx is launching a ground-breaking clinical</description>
</item>
<item>
<title>Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-discuss-full-fourth-130100929</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-discuss-full-fourth-130100929</guid>
<pubDate>Mon, 16 Feb 2026 13:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open.</description>
</item>
<item>
<title>USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/uspto-grants-acurx-pharmaceuticals-patent-130000754</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/uspto-grants-acurx-pharmaceuticals-patent-130000754</guid>
<pubDate>Mon, 02 Feb 2026 13:00:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the United States Patent and Trademark Office has granted a new U.S. patent, US 12,534,470. This latest patent, which covers DNA Polymerase IIIC inhibitors including compositions‑of‑matter, methods of use, and pharmaceutical compositions, further strengthens Acurx's inte</description>
</item>
<item>
<title>Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/health-holland-awards-another-innovative-130000059</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/health-holland-awards-another-innovative-130000059</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Health~Holland has awarded another grant of approximately $375,000 USD to Leiden University Medical Center (LUMC) and, through a three-party Consortium Agreement, Acurx Pharmaceuticals. The grant will fund this innovative research project entitled: POLSTOP4MDRO – Assessing conservat</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-reports-third-120100549</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-reports-third-120100549</guid>
<pubDate>Wed, 12 Nov 2025 12:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-publication-nature-communications-130000837</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-publication-nature-communications-130000837</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections announced the publication of results from its scientific collaboration with Leiden University Medical Center (LUMC) demonstrating structural biology research that reveals for the first time a DNA pol IIIC inhibitor, ibezapolstat, bound to its target. The publication is entitled: A unique inhi</description>
</item>
<item>
<title>Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-data-dna-pol-120000430</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-data-dna-pol-120000430</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections. It announced today that a presentation was given by Michael Silverman, MD, FACP, Acurx's Medical Director, and Kevin Garey, PharmD, MS, FIDSA, Professor and Chair, University of Houston College of Pharmacy, Principal Investigator for microbiology and microbiome aspects of the ibezapolstat clinical trial</description>
</item>
<item>
<title>Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-discuss-third-quarter-120000300</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-discuss-third-quarter-120000300</guid>
<pubDate>Mon, 27 Oct 2025 12:00:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 am ET before the U.S. financial markets open.</description>
</item>
<item>
<title>Meet the Companies - New to The Street's Accredited Investor Event Returns October 21-22 at Hudson Yards, NYC</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/meet-the-companies-new-to-the-streets-accredited-investor-event-returns-october-21-22-at-hudson-yards-nyc-2</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/meet-the-companies-new-to-the-streets-accredited-investor-event-returns-october-21-22-at-hudson-yards-nyc-2</guid>
<pubDate>Fri, 10 Oct 2025 19:35:00 GMT</pubDate>
<description>NEW YORK CITY, NEW YORK / ACCESS Newswire / October 10, 2025 /New to The Street, one of the nation's longest-running business television brands airing as sponsored programming on Fox Business and Bloomberg, announces its upcoming "Meet the Companies" ...</description>
</item>
<item>
<title>Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/australian-patent-office-grants-acurx-113000496</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/australian-patent-office-grants-acurx-113000496</guid>
<pubDate>Thu, 09 Oct 2025 11:30:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Australian Patent Office. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of- matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect it</description>
</item>
<item>
<title>Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-positive-opinion-ema-113000221</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-announces-positive-opinion-ema-113000221</guid>
<pubDate>Tue, 30 Sep 2025 11:30:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections announced receipt of a favorable opinion from the PDCO of the EMA on Acurx's Pediatric Investigation Plan (PIP) for ibezapolstat use in children with C. difficile infection (CDI).</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-nasdaqacxp-resigns-with-new-to-the-street-for-long-form-interviews-national-tv-commercials-earned-media-and-accredited-investor-events</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-nasdaqacxp-resigns-with-new-to-the-street-for-long-form-interviews-national-tv-commercials-earned-media-and-accredited-investor-events</guid>
<pubDate>Sat, 06 Sep 2025 04:00:00 GMT</pubDate>
<description>NEW YORK CITY, NY / ACCESS Newswire / September 6, 2025 / New to The Street, one of the nation's premier financial media platforms, today announced that Acurx</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-regains-full-110100077</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-regains-full-110100077</guid>
<pubDate>Wed, 03 Sep 2025 11:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it had received notification letters from The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the minimum $1.00 bid price under Nasdaq Listing Rule 5550(a)(2), and the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1).</description>
</item>
<item>
<title>Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update</title>
<link>https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-reports-second-110100118</link>
<guid isPermaLink="true">https://6ix.com/company/acurx-pharmaceuticals-llc/news/acurx-pharmaceuticals-inc-reports-second-110100118</guid>
<pubDate>Tue, 12 Aug 2025 11:01:00 GMT</pubDate>
<description>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2025.</description>
</item>
</channel>
</rss>